HUMAN RECOMBINANT EP4 RECEPTOR
MULTISCREEN™ DIVISION ARRESTED CELL LINE
1 vial (4 x 106) frozen cells
Sigma Freezing Medium (C-6164)
Expression vector containing full-length human PTGER4 cDNA (GenBank Accession Number NM_000958) with FLAG tag sequence at N-terminus
Liquid nitrogen upon receiving
Propagation Medium: DMEM, 10% FBS
Stable for 1-2 days after thawing
Background: The human prostaglandin E2 (PGE2) receptor EP4 (or PTGER4) is abundantly expressed. Activation of EP4 receptor induces osteoblasts and thereby stimulates de novo bone formation. Results from targeted deletion of the EP4 receptor also suggest that the EP4 subtype of the PGE2 receptor is involved in lipopolysaccharide-induced bone resorption. Modulating EP4 action may thus prove to be clinically useful for the treatment of bacterially induced bone loss, such as in periodontitis and osteomyelitis. EP4 also plays a role in the anti-inflammatory action of PGE2 in human macrophage.
Application: Functional assays
Figure 1. Dose-dependent accumulation of intracellular cAMP upon treatment with ligand, measured with MultiscreenTM TR-FRET cAMP 1.0 No Wash Assay Kit (Multispan MSCM01).
Morath et al. (1999) Immunolocalization of the four prostaglandin E2 receptor proteins EP1, EP2, EP3, and EP4 in human kidney. J Am Soc Nephrol 10:1851-1860.
Zhang et al. (2000) Characterization of murine vasopressor and vasodepressor prostaglandin E(2) receptors. Hypertension 35:1129-1134.
Li X et al. (2009) Prostaglandin E(2) and its cognate EP receptors control human adult articular cartilage homeostasis and are linked to the pathophysiology of osteoarthritis. Arthritis Rheum 60:513-523.